Predict your next investment

Corporation
HEALTHCARE | Drug Manufacturing
dompe.com

See what CB Insights has to offer

Investments

8

Portfolio Exits

8

Partners & Customers

2

About Dompe Farmaceutici

Dompe Farmaceutici is engaged in the development and distribution of ethical drugs and self-medication, adjuvants, medical devices, and cosmetics. It also specializes in the fields of vitamins and mineral supplements and personal hygiene. It is based in Milan, Italy.

Dompe Farmaceutici Headquarter Location

via Santa Lucia, 6

Milan, 20122,

Italy

+39 02583381

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Dompe Farmaceutici Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Dompe Farmaceutici Rank

Latest Dompe Farmaceutici News

Global High Affinity Nerve Growth Factor Receptor Market Demand 2018- Dompe Farmaceutici SpA, Genzyme Corp, Handok Inc, Ignyta Inc, Loxo Oncology Inc, Merck & Co Inc, Nerviano Medical Sciences Srl, Plexxikon Inc, Proximagen Ltd, Rottapharm Bio

Sep 6, 2018

Hiren September 6, 2018 3 minutes read The global “ High Affinity Nerve Growth Factor Receptor market ” report provides a penetrating analysis of the High Affinity Nerve Growth Factor Receptor market. The report offers a concise outline of the market and describes the main terminologies of the market. The report has enclosed few of the prominent players in the global High Affinity Nerve Growth Factor Receptor market along with their share in the market to evaluate their development during the forecast duration. In this report, the global High Affinity Nerve Growth Factor Receptor market is valued at USD XX million in 2018 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2018 and 2025. The leading market players are Array BioPharma Inc, Astellas Pharma Inc, AstraZeneca Plc, Daiichi Sankyo Co Ltd, Dompe Farmaceutici SpA, Genzyme Corp, Handok Inc, Ignyta Inc, Loxo Oncology Inc, Merck & Co Inc, Nerviano Medical Sciences Srl, Plexxikon Inc, Proximagen Ltd, Rottapharm Bio. The report also takes into account the latest enhancements while foretelling the expansion of the key players. Get Free Sample Copy Here @:  http://www.marketresearchstore.com/report/global-high-affinity-nerve-growth-factor-receptor-market-279512#RequestSample The report also evaluates the High Affinity Nerve Growth Factor Receptor market size in the last few years. The study evaluates the global High Affinity Nerve Growth Factor Receptor market in terms of revenue [USD Million] and volume [k MT]. Further, the report also embraces the key restraints and drivers influencing the market growth as well as finds out the evaluation of the market for the forecast period. The report also entails the rising trends coupled with the major avenues for the growth of the High Affinity Nerve Growth Factor Receptor market. Furthermore, the main product type and segments and the sub-segments of the High Affinity Nerve Growth Factor Receptor market are depicted in the report. This brief summary involves business overview, most recent events, product offering, revenue share, strategies, and service offering of the dominant players. Moreover, the complete value chain of the market is also presented in the report coupled with the analysis of the downstream and upstream elements of the market. The global High Affinity Nerve Growth Factor Receptor market is classified based on the types of product and the end-user application segments. The market analysis determines the growth of every segment of the High Affinity Nerve Growth Factor Receptor market mentioned in the report. The data presented in the report is a compilation from diverse industry bodies to estimate the development of the segments in the coming period. Read full Research Report Study at @:  http://www.marketresearchstore.com/report/global-high-affinity-nerve-growth-factor-receptor-market-279512 The report also assesses the market growth across major regional segments. The global High Affinity Nerve Growth Factor Receptor market is classified on the basis of geography as Europe, Asia Pacific, Latin America, North America, and Middle East & Africa. Apart from this, the report also covers the competitive scenario existing in the global High Affinity Nerve Growth Factor Receptor market. There are 15 Chapters to display the Global High Affinity Nerve Growth Factor Receptor market Chapter 1, Definition, Specifications and Classification of High Affinity Nerve Growth Factor Receptor , Applications of High Affinity Nerve Growth Factor Receptor , Market Segment by Regions; Chapter 2, Manufacturing Cost Structure, Raw Material and Suppliers, Manufacturing Process, Industry Chain Structure; Chapter 3, Technical Data and Manufacturing Plants Analysis of High Affinity Nerve Growth Factor Receptor , Capacity and Commercial Production Date, Manufacturing Plants Distribution, R&D Status and Technology Source, Raw Materials Sources Analysis; Chapter 4, Overall Market Analysis, Capacity Analysis (Company Segment), Sales Analysis (Company Segment), Sales Price Analysis (Company Segment); Chapter 5 and 6, Regional Market Analysis that includes United States, China, Europe, Japan, Korea & Taiwan, High Affinity Nerve Growth Factor Receptor Segment Market Analysis (by Type); Chapter 7 and 8, The High Affinity Nerve Growth Factor Receptor Segment Market Analysis (by Application) Major Manufacturers Analysis of High Affinity Nerve Growth Factor Receptor ; Chapter 9, Market Trend Analysis, Regional Market Trend, Market Trend by Product Type, Market Trend by Application; Chapter 10, Regional Marketing Type Analysis, International Trade Type Analysis, Supply Chain Analysis; Chapter 11, The Consumers Analysis of Global High Affinity Nerve Growth Factor Receptor ; Chapter 12, High Affinity Nerve Growth Factor Receptor Research Findings and Conclusion, Appendix, methodology and data source; Chapter 13, 14 and 15, High Affinity Nerve Growth Factor Receptor sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source. Enquire Here Get customization & check discount for report @:  http://www.marketresearchstore.com/report/global-high-affinity-nerve-growth-factor-receptor-market-279512#InquiryForBuying Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe, South America, Middle East & Africa. Post Views: 1

Dompe Farmaceutici Investments

8 Investments

Dompe Farmaceutici has made 8 investments. Their latest investment was in Engitix as part of their Series A - II on January 1, 2022.

CBI Logo

Dompe Farmaceutici Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

1/19/2022

Series A - II

Engitix

$54M

Yes

11

4/10/2020

Series C

Subscribe to see more

$99M

Subscribe to see more

10

12/18/2019

Corporate Minority

Subscribe to see more

$99M

Subscribe to see more

10

7/25/2016

Corporate Minority

Subscribe to see more

$99M

Subscribe to see more

10

1/17/2012

Corporate Minority

Subscribe to see more

Subscribe to see more

0

Date

1/19/2022

4/10/2020

12/18/2019

7/25/2016

1/17/2012

Round

Series A - II

Series C

Corporate Minority

Corporate Minority

Corporate Minority

Company

Engitix

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$54M

$99M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

11

10

10

10

0

Dompe Farmaceutici Portfolio Exits

8 Portfolio Exits

Dompe Farmaceutici has 8 portfolio exits. Their latest portfolio exit was Dompe Farmaceutici - Rigentex on November 25, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

11/25/2021

Divestiture

1

11/25/2021

Divestiture

Subscribe to see more

Subscribe to see more

10

11/25/2021

Divestiture

Subscribe to see more

Subscribe to see more

10

11/25/2021

Divestiture

Subscribe to see more

Subscribe to see more

10

11/25/2021

Divestiture

Subscribe to see more

Subscribe to see more

10

Date

11/25/2021

11/25/2021

11/25/2021

11/25/2021

11/25/2021

Exit

Divestiture

Divestiture

Divestiture

Divestiture

Divestiture

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

10

Dompe Farmaceutici Acquisitions

1 Acquisition

Dompe Farmaceutici acquired 1 company. Their latest acquisition was Anabasis on February 29, 2012.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

2/29/2012

Other

$99M

Acquired

Date

2/29/2012

Investment Stage

Other

Companies

Valuation

$99M

Total Funding

Note

Acquired

Sources

Dompe Farmaceutici Partners & Customers

2 Partners and customers

Dompe Farmaceutici has 2 strategic partners and customers. Dompe Farmaceutici recently partnered with Engitix on January 1, 2022.

Date

Type

Business Partner

Country

News Snippet

Sources

1/19/2022

Partner

United Kingdom

Engitix Announces $54m Series A Financing and a Strategic Collaboration with Dompé Farmaceutici Using Exscalate’s AI Supercomputing Power to Advance its Drug Discovery Pipeline in Fibrosis and Cancer

Dr Giuseppe Mazza co-founder and CEO of Engitix Ltd said , `` This financing and new partnership with Dompé farmaceutici S.P.A enables us to continue our evolution from a platform to multi-asset mutli-programmes pre-clinical stage company and to continue to prove the value of our human ECM platform .

2

7/30/2020

Licensee

United States

Subscribe to see more

Subscribe to see more

10

Date

1/19/2022

7/30/2020

Type

Partner

Licensee

Business Partner

Country

United Kingdom

United States

News Snippet

Engitix Announces $54m Series A Financing and a Strategic Collaboration with Dompé Farmaceutici Using Exscalate’s AI Supercomputing Power to Advance its Drug Discovery Pipeline in Fibrosis and Cancer

Dr Giuseppe Mazza co-founder and CEO of Engitix Ltd said , `` This financing and new partnership with Dompé farmaceutici S.P.A enables us to continue our evolution from a platform to multi-asset mutli-programmes pre-clinical stage company and to continue to prove the value of our human ECM platform .

Subscribe to see more

Subscribe to see more

Sources

2

10

Dompe Farmaceutici Team

6 Team Members

Dompe Farmaceutici has 6 team members, including current Chief Executive Officer, Nathalie Dompé.

Name

Work History

Title

Status

Nathalie Dompé

Chief Executive Officer

Current

Sergio Dompé

President

Current

Giuseppe Andreano

Chief Financial Officer

Current

Eriona Gjinukaj

Chief Operating Officer

Current

Davide Polimeni

Chief Commercial Officer

Current

Name

Nathalie Dompé

Sergio Dompé

Giuseppe Andreano

Eriona Gjinukaj

Davide Polimeni

Work History

Title

Chief Executive Officer

President

Chief Financial Officer

Chief Operating Officer

Chief Commercial Officer

Status

Current

Current

Current

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.